December 26, 2016
Chugai Pharmaceutical said on December 22 that it has obtained exclusive rights in Japan to develop and commercialize PM1183 (lurbinectedin), a marine-derived anticancer agent, from Spanish drug biopharmaceutical maker PharmaMar. Under the deal, PharmaMar will receive an upfront payment of...read more